Yesterday was an interesting day. I took a step back and looked at the chart and while you might think I am crazy, if you squint in the right way it looks like we have already broken out. Maybe. If we use $87 as the top of the range, then we broke above it on […]
January 30th Biotech Update
I feel like a broken record as we start yet another week with the potential to break out to the upside but not the best start in that attempt. There is not a lot to cover today, so it will be quick but we do have earnings that could be an excuse for the move […]
January 27th Biotech Update
The sector is teasing us. I thought this week had the potential to see a breakout and we are right at the levels. It would be nice to see a clear move above resistance and then a back test in the next week or two to confirm. We have earnings upcoming and that will either […]
January 25th Biotech Update
Are we setting up for that breakout? Just like last week we are in the position to do so but remember last week we ended up failing. While I am not sure there is any fundamental reason for us to breakout as there is not a ton of new, I do get the sense that […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
